Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IAPP | P10997 | 1/20 | 0.36 |
| ▸ | MGMT | P16455 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22284116 | 0.84 | GAA (0.40) | GAALMNAALDH1A1TDP1KMT2A | |
| SCHEMBL2729457 | 0.83 | CXCL8 (0.47) | GAALMNATDP1KMT2AMEN1 | |
| SCHEMBL2729071 | 0.83 | CXCL8 (0.47) | GAALMNATDP1KMT2AMEN1 | |
| SCHEMBL214271 | 0.82 | ALDH1A1 (0.45) | GAALMNAALDH1A1TDP1KMT2A | |
| SCHEMBL4296586 | 0.81 | NLRP3 (0.47) | GAALMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL27836447 | 0.81 | PDGFRB (0.43) | GAALMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL13885226 | 0.78 | KMT2A (0.42) | GAALMNAALDH1A1KMT2AL3MBTL1 | |
| Ethylene SCHEMBL7406931 | 0.78 | HPGD (0.46) | GAALMNAALDH1A1TDP1KMT2A | |
| SCHEMBL7419247 | 0.77 | SMN1; SMN2 (0.47) | LMNAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL16397045 | 0.77 | MTNR1A (0.43) | GAALMNAL3MBTL1MGMTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687294-B1 | NOVEL PIPERIDINE-SUBSTITUTED INDOLES-OR HETERO-DERIVATIVES THEREOF AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR (CCR-3) | BOEHRINGER INGELHEIM INT (DE) | 2014-05-21 | — | — | EP | disclosed |
| EP-1994019-B1 | NOVEL PIPERIDIN - SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7544806-B2 | Piperidine-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| EP-1994019-A2 | NOVEL PIPERIDIN - SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | Boehringer Ingelheim International GmbH (DE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2006117314-A2 | NOVEL PIPERIDIN- SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | WO | disclosed |
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | US | disclosed |
| EP-1687294-A2 | NOVEL PIPERIDINE-SUBSTITUTED INDOLES-OR HETERO-DERIVATIVES THEREOF AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR (CCR-3) | Boehringer Ingelheim International GmbH (DE) | 2006-08-09 | — | — | EP | disclosed |
| US-20050153979-A1 | Novel piperidine-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| WO-2005049559-A2 | NOVEL PIPERIDINE-SUBSTITUTED INDOLES- OR HETERO-DERIVATIVES THEREOF AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR (CCR-3) | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153979-A1 | Novel piperidine-substituted indoles-or heteroderivatives thereof | CCR3, CCR1, CCR2 | GAA 4480/4885LMNA 3994/4885ALDH1A1 1284/4885 |
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | CCR3, CCR1, CCR2 | GAA 4748/4885LMNA 4228/4885ALDH1A1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.